drugset / Trial / NCT06465862

Development of a Silica Microparticle Taggant System to Measure ART Adherence

NCT06465862 ↗

NaSingle-groupOpen-labelOther

Summary

Developing technologies to help measure and provide tools to support medication-taking behaviors (medication adherence) is an important step to ending the human immunodeficiency virus (HIV) epidemic. TruTag Technologies has pioneered the use of a microparticle system that can be incorporated into the coating of medications may help users both identify the medication they are taking and record adherence events. By using a standard smartphone camera, shining light on TruTag-coated medications automatically identifies them to an onboard smartphone app which then indirectly records the adherence event. This study evaluates the real-world usability and feasibility of operating this system among people living with HIV (PLWH).

Timeline

Start
2024-09-15
Primary completion
2024-12-30
Completion
2025-04-15

Outcome

Outcome not reported

Stopped (Enrollment): “Study withdrawn prior to enrollment due to lack of funding.”

Drugs

EvaluationDrugModalityDoseRoute
Background Bictegravir/Emtricitabine/Tenofovir Alafenamide Unknown — Oral